Therapy for HRpos HER2neg MBC

CE / CME

Individualizing Therapy for Patients With HR+/HER2- MBC

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Released: February 18, 2025

Expiration: August 17, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case 3: MBC After Adjuvant ET



  • 62-yr-old woman was initially diagnosed with stage IIA ER+/HER2- breast cancer 7 yr ago

  • She underwent surgery, adjuvant TC x 4 chemotherapy, and completed 5 yr of adjuvant letrozole therapy 2 yr ago

  • She presented recently with persistent back pain, for which she has had to take ibuprofen

  • Further imaging disclosed widespread bone lesions consistent with metastatic breast cancer and supraclavicular lymphadenopathy

  • Laboratory testing is normal aside from elevated alkaline phosphatase

  • Node biopsy confirmed metastatic breast cancer, ER+/HER2 1+

  • ctDNA evaluation notable for lack of ESR1 or PIK3CA mutations 

Which first-line systemic therapy would you recommend?